Table 3 The reported targeted therapy cases of PACC
From: Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review
Ref. | Sex; Age; Smoking | Gene mutation | Targeted therapy | Response | Outcomes | PFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|
[10] | F; 50; No | No | Bevacizumab | SD | Alive | About 12 | About 48 |
[31] | F; 37; No | ERBB (+) | Pyrotinib | SD | Alive | 6 | About 168 |
[43] | F; 80; NM | EGFR exon 18 (+) | Gefitinib | PR | Died | 6 | 19 |
[50] | M; 42; Yes | c-kit (+) | Imatinib | PR | Alive | 12 | NM |
[52] | F; 60; No | EGFR exon 21 (+) | Erlotinib | SD | Died | 8 | 33 |
[53] | M; 29; No | EGFR exon 19 (+) | Icotinib | SD | Alive | 19 | 179 |